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Abstract
Aims—To determine the prevalence of plasma vitamin D insufficiency in individuals with Type 1 
diabetes and to determine the cross-sectional and longitudinal associations of plasma vitamin D 
with insulin resistance.
Methods—Participants from the SEARCH for Diabetes in Youth Study [n = 1426; mean age 
11.2 years (SD 3.9)] had physician-diagnosed Type 1 diabetes [diabetes duration mean 10.2 months 
(SD 6.5)] with data available at baseline and follow-up (approximately 12 and 24 months after 
baseline). Insulin resistance was estimated using a validated equation. Cross-sectional and 
longitudinal multivariate logistic regression models were used to determine the association of 
plasma vitamin D with insulin resistance, adjusting for potential confounders.
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Results—Forty-nine per cent of individuals had plasma vitamin D < 50 nmol/l and 26% were 
insulin resistant. In cross-sectional multivariate analyses, participants who had higher plasma 
vitamin D (65 nmol/l) had lower odds of prevalent insulin resistance than participants with lower 
plasma vitamin D (25 nmol/l) (odds ratio 0.70, 95% CI 0.57–0.85). This association was 
attenuated after additional adjustment for BMI z-score, which could be a confounder or a mediator 
(odds ratio 0.81, 95% CI 0.64–1.03). In longitudinal multivariate analyses, individuals with higher 
plasma vitamin D at baseline had lower odds of incident insulin resistance, but this was not 
significant (odds ratio 0.85, 95% CI 0.63–1.14).
Conclusions—Vitamin D insufficiency is common in individuals with Type 1 diabetes and may 
increase risk for insulin resistance. Additional prospective studies are needed to determine the 
association between plasma vitamin D and insulin resistance, and to further examine the role of 
adiposity on this association.
Introduction
Beta-cell loss and absolute insulin deficiency are the primary issues facing individuals with 
Type 1 diabetes. However, a growing percentage of these youth are overweight and obese 
[1], which is concerning given the relationship between obesity and insulin resistance [2]. 
Moreover, approximately 20% of individuals with Type 1 diabetes are insulin resistant [3]. 
Given that insulin resistance increases cardiovascular risk [4], the identification of 
modifiable factors that improve insulin resistance may be critical for maintaining glycaemic 
control and improving long-term health outcomes in individuals with Type 1 diabetes.
The mechanisms underlying the relationship between vitamin D and insulin resistance are 
not completely understood. 1,25-dihydroxyvitamin D [1,25(OH)2D], the biologically active 
form of vitamin D, has been shown to enhance insulin-mediated glucose transport [5] and 
activate the transcription of the insulin receptor gene [6]. Further, vitamin D receptors are 
expressed in skeletal and adipose tissues [7], main sites of peripheral glucose uptake. 
Findings from epidemiological studies have been mixed with inverse [8–13] and null 
[11,14,15] associations reported. Given discrepant findings, the prevalence of obesity and 
insulin resistance among youth with Type 1 diabetes and the potential contribution of insulin 
resistance to cardiovascular risk in this vulnerable population, additional studies are needed.
The SEARCH for Diabetes in Youth (SEARCH) study provides a unique opportunity to 
explore the potential role of vitamin D in a large ethnically and regionally diverse cohort of 
youth with clinically diagnosed Type 1 diabetes. US data suggest a high prevalence of 
inadequate vitamin D levels in children [16], thus our aims were to determine the prevalence 
of low concentrations of 25-dihydroxyvitamin D [25(OH)D, the indicator of vitamin D 
status] in individuals with Type 1 diabetes and to determine the cross-sectional association 
of 25(OH)D with insulin resistance. We hypothesized that higher levels of 25(OH)D levels 
would be inversely associated with insulin resistance. Further we aimed to investigate the 
association of 25(OH)D with incident insulin resistance, hypothesizing that individuals with 
higher levels of 25(OH)D would be less likely to become insulin resistance than individuals 
with lower levels of 25(OH)D.
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Data for this study derive from the SEARCH Study and the SEARCH Nutrition Ancillary 
Study. The parent SEARCH study [17,18] ascertained cases of diabetes diagnosed when 
subjects were < 20 years of age, starting in 2002 and continuing through to the present. 
Participants with newly diagnosed diabetes in 2002–2005 were invited to participate in a 
baseline research visit (mean diabetes duration at visit 10.5 months) and two follow-up visits 
approximately 12 and 24 months after their baseline visit. At each research visit, fasting 
blood samples were obtained from metabolically stable participants (defined as no episode 
of diabetic ketoacidosis during the previous month), physical measurements were conducted 
and questionnaires were administered. For SEARCH participants with Type 1 diabetes 
diagnosed in 2002–2005, SEARCH Nutrition Ancillary Study collected additional 
nutritional data, including plasma measures of 25(OH)D (nmol/l) obtained from frozen 
samples (stored at −80 °C) collected at the baseline and first follow-up SEARCH visits. 
Both studies were reviewed and approved annually by the local Institutional Review 
Board(s) that had jurisdiction over the local study population and complied with the Health 
Insurance Portability and Accountability Act. All participants provided informed consent 
and/or assent.
SEARCH data
Fasting blood samples were analysed to measure diabetes autoantibodies, HbA1c and lipids. 
Glutamic acid decarboxylase 65 (GAD65) and insulinoma-associated 2 (IA-2) diabetes 
autoantibodies were analysed using a standardized protocol and a common serum calibrator 
developed by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK)-sponsored standardization group [19]. Cut-off values for positivity were GAD65 
≥ 33 NIDDKU/ml and IA-2 5 ≥ NIDDKU/ml for IA-2 [19]. HbA1c was measured in whole 
blood with an automated non-porous ion-exchange high-performance liquid chromatography 
system (model G-7; Tosoh Bioscience Inc., San Francisco, CA, USA). Lipid measurements, 
including triglycerides, were performed using Roche reagent on a Roche Modular-P 
Autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). Human leucocyte antigen class II 
genotyping (HLA DR/DQ) was performed with a PCR-based sequence-specific 
oligonucleotide probe system in the laboratories of the University of Washington (Seattle, 
WA, USA) and Roche Molecular Systems Pleasanton, CA, USA).
BMI (kg/m2) z-scores from measured height and weight were derived for age and gender 
using the US Centers for Disease Control and Prevention (CDC) National Center for Health 
Statistics growth charts [20]. Waist circumference was measured using the National Health 
and Nutrition Examination Survey (NHANES) III protocol [21].
A surrogate measure of insulin resistance, appropriate for youth with Type 1 diabetes, was 
derived from the following equation: Insulin sensitivity score = exp[4.64725 − 
0.02032*(waist circumference, cm) − 0.09779 × (HbA1c, − 0.00235 × (triglyceride, mg/dl)]. 
A detailed description of the development and validation of this equation has been published 
elsewhere [22]. Briefly, a subset of participants from SEARCH(n = 85; ages 12–19 years) 
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underwent a 3-h euglycaemic–hyperinsulinaemic clamp to measure glucose disposal rate. 
Multivariate linear regression was used to estimate a surrogate measure insulin sensitivity 
score, with waist circumference explaining 60% of the variance in measured glucose 
disposal rate. The formula was reproduced and validated in youth with diabetes (Type 1 and 
Type 2) and healthy control subjects. Consistent with previous SEARCH analysis [3], the 
insulin sensitivity score was dichotomized to define insulin resistance (< 8.15) and insulin 
sensitivity (≥ 8.15).
Self-reported race and ethnicity were collected using 2000 US Census questions and, for this 
analysis, categorized as non-Hispanic white, African-American and ‘other’ [23]. 
Information about treatment regimen, including type(s) of insulin, total daily insulin dose, 
frequency of insulin injections or use of continuous subcutaneous insulin infusion (insulin 
pump) were also collected.
For participants ages ≥ 10 years, SEARCH ascertained physical activity status and pubertal 
development via questionnaire [24]. Moderate to vigorous physical activity was defined as ≥ 
3 days/week of any activity that either tones or makes one sweat. Pubertal development was 
self-reported using the standard technique described by Marshall and Tanner [25,26]. For a 
sensitivity analysis, participants who were aged < 10 years were assumed to be prepubertal.
SEARCH Nutrition Ancillary Study data
25(OH)D was measured using the direct, competitive chemiluminescence immunoassay 
developed by Dia Sorin (Stillwater, MN, USA) [universal naming convention (UNC) 
detectable range, 5–320 nmol/l; intra-assay coefficient of variation, 11.0%], based on a 
linkage between specific vitamin D antibody coated magnetic particles and an isoluminol 
derivative. This method uses an antibody as a primary binding agent and measures 
25(OH)D2 and 25(OH)D3 [27]. There were n = 12 at baseline and n = 3 at follow-up, with 
25(OH)D values below the detectable limit and set to 4.9 nmol/l for this analysis. For 
descriptive analysis, 25(OH)D was categorized as: (1) risk of deficiency (< 30.0); (2) risk of 
inadequacy (30.0–49.9); (3) sufficient (50.0–125.0); and (4) possibly harmful (> 125.0) [28]. 
For multivariate analysis, 25(OH)D was utilized as a continuous variable.
Participant inclusion
‘Type 1 diabetes’ was defined by physicians’ report of ‘Type 1’, ‘Type 1a’ or ‘Type 1b’ 
diabetes. Cross-sectional analysis included data from individuals with Type 1 diabetes who 
had measurements of 25(OH)D and an insulin sensitivity score at baseline, resulting in an 
analytic sample of 1426 individuals. For longitudinal analyses, participants from the cross-
sectional analytic sample who had insulin resistance data at the 12- and/or 24-month follow-
up visits were selected for inclusion. Given our interest in determining the association 
between 25(OH)D and incident insulin resistance, participants who were insulin resistant at 
baseline were excluded, resulting in a longitudinal sample of 735 participants. For 
participants who had measures of insulin resistance from two follow-up visits, data from 
their 24-month follow-up visit was used.
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Analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC, USA), with P < 
0.05 indicating significance, except where otherwise stated. Comparisons of baseline 
percentages and mean values by participant characteristics were examined using χ2-tests and 
analysis of variance (ANOVA). Trends in exposure and outcomes were examined using 
paired t-tests and multiple linear regression in the sub-population of individuals who had 
measurements at both baseline and follow-up and were not insulin resistance at baseline.
To determine the association of 25(OH)D with insulin resistance at baseline, a series of 
multivariate logistic regression models were fitted, first adjusted for diabetes duration only, 
then for covariates shown to be associated with 25(OH)D and/or insulin resistance (age, 
gender, race/ethnicity, HLA genotype, insulin regimen, clinical site and season of visit). 
Although pubertal status and physical activity may also be confounders, these data were 
collected in participants aged ≥ 10 years only and we wanted to retain the full, larger sample 
for primary analyses. Thus, pubertal status and physical activity were included in subsequent 
separate models for the subset of individuals with these measures. Further, previous research 
suggests that adiposity may be a mediator and/or confounder of the association between 
25(OH)D and insulin resistance; consequently, additional analyses were conducted 
including BMI z-score in the full, larger sample. Finally, we had an a priori interest in 
determining whether the association between 25(OH)D and insulin resistance varied by 
disease duration, age, HLA genotype, race/ethnicity and BMI z-score; thus, we examined 
effect modification using separate interaction terms and likelihood ratio tests (P < 0.1). To 
facilitate clinical interpretation, odds ratios and 95% confidence intervals were obtained by 
comparing a difference of 40 nmol/l in 25(OH)D, which reflects a comparison between 
being at risk for 25(OH)D deficiency (25 nmol/l) and being sufficient for 25(OH)D (65 
nmol/l).
Using the longitudinal sample to determine if baseline 25(OH)D is associated with incident 
insulin resistance, we used a similar series of multivariate logistic regression models to that 
of the cross-sectional models, but also included the change in time-varying covariates. As 
with the cross-sectional models, the estimated odds ratio and 95% confidence intervals 
reflect the odds of incident insulin resistance, given a 40 nmol/l change in 25(OH)D.
As the use of a dichotomous cut point to define insulin resistance would reduce our power to 
identify a small association, we repeated all multivariate analysis using linear regression to 
determine the relation between 25(OH)D and the continuous insulin sensitivity score. 
Finally, for a sensitivity analysis, all multivariate analyses were repeated in the subsample of 
participants who had physician-diagnosed Type 1 diabetes and had at least one instance of 
positive diabetes autoantibodies (GAD65 or IA-2: n = 1211).
Results
Cross-sectional sample
Forty-nine per cent of individuals were at risk of deficiency or at risk of insufficiency for 
vitamin D [25(OH)D < 50.0 nmol/l]. Compared with those who were vitamin D sufficient, 
these participants were more likely to be non-white, older at baseline and to have had their 
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research visit during the winter months (Table 1; all P < 0.05). They also tended to have 
lower insulin sensitivity scores, and higher BMI z-scores, triglycerides and waist 
circumference (all P < 0.05). Individuals with insulin resistance were older, had lower 
25(OH)D, longer diabetes duration and higher BMI z-score, HbA1c, triglycerides and waist 
circumference (Table 2; all P < 0.05). Further, the prevalence of insulin resistance was 
significantly higher among race/ethnic minorities than non-Hispanic white people.
Multivariate analysis revealed that the cross-sectional association between 25(OH)D and 
insulin resistance did not vary by age at baseline, diabetes duration, HLA genotype and BMI 
z-score (each interaction P ≥ 0.1); thus, the interaction terms were not included in any of the 
models.
Higher 25(OH)D was significantly inversely associated with insulin resistance (Table 3; 
model 2), both before and after adjustment for diabetes duration, age, race/ethnicity, gender, 
insulin regimen, HLA genotype, clinical site and season of clinical visit. Participants who 
had sufficient levels of 25(OH)D (65 nmol/l) had an adjusted odds ratio of insulin resistance 
that was 0.70 times that of participants who were at risk of 25(OH)D deficiency (25 nmol/l) 
(95% CI 0.57– 0.85). Despite smaller sample sizes, because of restriction by design to 
participants ages ≥ 10 years, separate adjustment for pubertal status (model 3) and physical 
activity (model 4) yielded similar, statistically significant associations. However, as 
expected, adjustment for BMI z-score (model 5) in the larger cross-sectional sample resulted 
in an attenuation of the association (odds ratio 0.81, 95% CI 0.64–1.03). Sensitivity analyses 
among participants with at least one instance of positive diabetes autoantibodies resulted in 
similar findings (results not presented).
In parallel analysis using multivariate, linear regression, a 40-unit increase in 25(OH)D was 
associated with a higher insulin sensitivity score (model 2 covariate adjustment: β-
coefficient = 0.50, 95% CI 0.33–0.68, P < 0.001). The association was attenuated but 
remained significant after further adjustment for BMI z-score (β-coefficient = 0.26, 95% CI 
0.11–0.40, P = 0.004).
Longitudinal sample
The longitudinal sample was similar to the cross-sectional sample at baseline (see Table 1) 
with respect to gender, HLA risk group, clinical site and season of visit (all P ≥ 0.05). 
However, the longitudinal sample had a higher percentage of non-Hispanic white youth 
(81.4%), was younger (10.3 ± 3.6 years), had higher 25(OH)D (63.0 ± 35.6 nmol/l), insulin 
sensitivity scores (12.0 ± 2.4) and shorter disease duration (9.0 ± 5.0 months) (all P < 0.05) 
than the cross-sectional sample. For individuals who had insulin sensitivity scores at both 
the baseline and follow-up examinations, insulin sensitivity scores declined significantly, 
from mean 12.0 ± 2.4 at baseline to 9.9 ± 2.8 at the follow-up visit (P < 0.01), suggesting 
worsening of insulin sensitivity with Type 1 diabetes progression.
Higher 25(OH)D at baseline was associated with reduced risk for incident insulin resistance 
at follow-up after adjustment for diabetes duration and time between research visit odds 
ratio 0.69, 95% CI 0.63–1.14) (Table 4). However, this association was no longer significant 
after adjustment for other potential confounders. Sensitivity analyses among participants 
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with at least one instance of positive diabetes autoantibodies, resulted in similar findings 
(results not presented).
In parallel analysis using multivariate, linear regression, a 40-unit increase in baseline 
25(OH)D appeared to be associated with higher insulin sensitivity score in follow-up (model 
2 covariate adjustment: β-coefficient = 0.12, 95% CI –0.04 to 0.27), but was not significant 
P = 0.15).
Discussion
In this large cohort of individuals with Type 1 diabetes, nearly half had 25(OH)D < 50.0 
nmol/l, with race/ethnic minorities (vs. non-Hispanic white people) and individuals with 
higher BMI z-score being disproportionately affected. The high proportion of individuals 
with vitamin D insufficiency is fairly consistent with studies of youth without diabetes [16].
Several cross-sectional studies report an inverse association between vitamin D and insulin 
resistance [8–11,14,15], but with interesting nuances. Nationally representative data showed 
an inverse relationship between 25(OH)D and insulin resistance among non-Hispanic white 
people and Mexican-Americans, but not in non-Hispanic black people, suggesting 
differential relationship by race/ethnicity [11]. However, our data showed no evidence of 
effect modification by race/ethnicity. Two other studies observed an inverse association 
between 25(OH)D and insulin resistance only prior to adjustment for BMI [14,15].
The complex influence of adiposity on the relation between 25(OH)D and insulin resistance 
remains poorly understood. Obese individuals have lower levels of 25(OH)D than lean 
individuals [29], which may be related to sequestering and storage of vitamin D in adipose 
tissue [30]. Alternatively, others report a strong correlation of 25(OH)D in subcutaneous fat 
and serum [31], suggesting that serum 25(OH)D levels accurately reflect levels in adipose 
tissue. Given this complex relationship of vitamin D with adipose tissue, and the strong 
impact of obesity on insulin resistance [2], adjustment in statistical models for BMI may be 
appropriate if obesity is a confounder, but may also be an over-adjustment to the extent that 
obesity is involved in relevant biological pathways. In our cross-sectional analysis, 
adjustment for BMI z-score resulted in an attenuated effect. However, it is not possible to 
discern if the BMI z-score adjusted result is the best estimate of the true association or if the 
best estimate is that obtained after adjustment only for potential confounders not including 
BMI z-score. Additional analyses examining effect modification by obesity status were not 
significant, suggesting a similar association for individuals who are overweight/obese and 
normal weight. Understanding the role of adiposity on the relation of 25(OH)D with insulin 
resistance is an area of great research potential.
The few studies examining the longitudinal association between 25(OH)D and insulin 
resistance were conducted in older adults and observed inverse associations [12,13]. Our 
longitudinal analyses revealed that higher 25(OH)D was associated with a lower odds of 
becoming insulin resistant, although this was not statistically significant after adjustment for 
potential confounders. The reason for the difference in statistical significance across studies 
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may be attributed to population differences, sample size or methods to assess insulin 
resistance.
There are some limitations, as well as strengths, to our study. First, we only have 
measurements of 25(OH)D and do not have information about 1,25(OH)D, vitamin D 
binding protein, vitamin D receptors or vitamin D receptor genotype. Additionally, the 
immunoassay we used to measure 25(OH)D did not distinguish between 25(OH)D2 and 
25(OH)D3; thus, if only one form of 25(OH)D had an effect on insulin resistance, we would 
have been unable to capture this effect. Second, our analytic sample was limited to 
individuals who participated in the SEARCH visit and had sufficient availability of stored 
plasma. However, there is little reason to suppose that the biological relation between 
25(OH)D and insulin resistance would differ between participants and non-participants. We 
repeated our cross-sectional analysis restricted to the longitudinal sample and found 
identical associations, suggesting no evidence of selection bias. A final limitation is that our 
findings may be affected by residual confounding; however, several sensitivity analyses 
were conducted to examine the potential effect of residual confounding by pubertal status 
and physical activity, finding none.
The strengths of our study include our use of the SEARCH study, a diverse contemporary 
sample of youth with provider-diagnosed Type 1 diabetes followed prospectively over time. 
Most research in this area has been conducted using cross-sectional designs and in 
individuals without diabetes, thus precluding the generalizability of these findings to at-risk 
populations. The large, well-characterized multi-ethnic sample allowed us to better 
understand the relationship between vitamin D and insulin resistance in an understudied yet 
medically vulnerable population. The availability of a validated measure of insulin 
sensitivity as developed and validated against the gold standard euglycaemic–
hyperinsulinaemic clamp [3,22] is a major strength of our study.
In summary, nearly half of individuals with Type 1 diabetes are at risk of deficiency or 
inadequate levels of vitamin D. Further, although not definitive, our findings suggest that 
25(OH)D may impact positively on insulin sensitivity. Future research should utilize 
additional prospective observational studies and clinical trials to determine the potential 
clinical relevance of 25(OH)D on insulin sensitivity and related markers of cardiovascular 
risk among individuals with Type 1 diabetes.
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• The identification of modifiable factors that improve insulin resistance may be 
critical for improving long-term health outcomes for individuals with Type 1 
diabetes.
• Previous studies examining the relation of vitamin D with insulin resistance 
have reported inconsistent findings.
• Most research in this area has been conducted using cross-sectional designs and 
in individuals without diabetes, thus precluding the generalizability of these 
findings to at-risk populations.
• Determining the relation of vitamin D with insulin in a diverse, contemporary 
cohort of youth with Type 1 diabetes may have implications for short- and long-
term health.
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Table 2
Baseline characteristics of youth with Type 1 diabetes diagnosed in 2002–2005 by insulin sensitivity score 
categories: SEARCH Nutrition Ancillary Study (cross-sectional sample, n = 1426)





Total sample at baseline, n (%) 1057 (74.1) 369 (25.9)
Race/ethnicity, n (%) < 0.001
  Non-Hispanic white 846 (78.0) 239 (22.0)
  African-American 88 (64.2) 49 (35.8)
  Other 123 (60.3) 81 (39.7)
Gender, n (%) 0.07
  Female 501 (72.0) 195 (28.0)
  Male 556 (76.2) 174 (23.8)
Age at visit (years) 10.3 ± 3.7 14.0 ± 3.0 < 0.001
Plasma vitamin D [(25)-OH, nmol/l] 60.9 ± 35.0 47.8 ± 29.5 < 0.001
Categories of 25(OH)D (nmol/l), n (%) < 0.001
  < 30.0 183 (61.0) 117 (39.0)
  30.0–49.9 292 (74.5) 100 (25.5)
  50.0–125.0 525 (78.7) 142 (21.3)
  > 125.0 57 (85.1) 10 (14.9)
Diabetes duration (months) 9.6 ± 6.2 11.7 ± 7.0 < 0.001
HbA1c (mmol/mol) 57 ± 13 72 ± 22 < 0.001
HbA1c (%) 7.4 ± 1.2 8.7 ± 2.0 < 0.001
BMI z-score* 0.4 ± 0.9 1.2 ± 0.9 < 0.001
Triglycerides (mg/dl) 55.9 ± 23.1 96.7 ± 54.6 < 0.001
Waist circumference (cm) 65.5 ± 9.4 86.8 ± 12.8 < 0.001
HLA risk group, n (%)† 0.26
  Low 509 (72.5) 193 (27.5)
  High/moderate 497 (75.2) 164 (24.8)
Insulin regimen, n (%)‡ 0.26
  Insulin pump 95 (75.4) 31 (24.6)
  Glargine + rapid-acting insulin 335 (72.5) 127 (27.5)
  Glargine + 2 or more insulins 76 (76.0) 24 (24.0)
  Multiple injections without glargine 145 (71.4) 58 (28.6)
  Two or fewer insulin injections 396 (78.0) 112 (22.1)
Clinical SEARCH site, n (%) 0.02
  South Carolina 194 (73.8) 69 (26.2)
  Ohio 219 (75.0) 73 (25.0)
  Colorado 333 (77.1) 99 (22.9)
  California 87 (66.4) 44 (33.6)
  Washington 206 (75.9) 69 (25.1)
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  Hawaii 18 (54.6) 15 (45.5)
Season of visit, n (%) 0.92
  Winter 274 (74.3) 95 (25.8)
  Spring 265 (74.2) 92 (25.8)
  Summer 294 (75.0) 98 (25.0)
  Autumn 224 (72.7) 84 (27.3)
Values are mean ± SD, unless specified otherwise.
*
10 individuals missing BMI z-score.
†
63 individuals missing human leucocyte antigen (HLA) genotype.
‡
27 individuals missing insulin regimen.
25(OH)D, 25-dihydroxyvitamin D.
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Table 3
Cross-sectional association between 25-dihydroxyvitamin D [25(OH)D] with prevalent insulin resistance 
(insulin sensitivity score < 8.15) in youth with Type 1 diabetes diagnosed in 2002–2005: SEARCH Nutrition 
Ancillary Study*
Odds ratio (95% CI)† n in model Covariates included in model
Model 1 0.59 (0.50–0.70) 1426 Diabetes duration
Model 2 0.70 (0.57–0.85) 1338 Diabetes duration, age at baseline, race/ethnicity, gender, insulin regimen, human 
leucocyte antigen (HLA) genotype, clinical site, season
Model 3 0.74 (0.60–0.92) 824 Model 2 covariates and physical activity[AW1]
Model 4 0.71 (0.56–0.90) 815 Model 2 covariates and Tanner stage
Model 5 0.81 (0.64–1.03) 1330 Model 2 covariates and BMI z-score
*
Logistic regression models were used to predict insulin resistance (< 8.15 vs. ≥ 8.15) by 25(OH)D (continuous).
†
Odds ratios and 95% confidence intervals were obtained by comparing a difference of 40 nmol/l in 25(OH)D [25(OH)D = 25 nmol/l (at risk of 
deficiency) vs. 25(OH)D = 65 nmol/l (sufficient)].
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Table 4
Longitudinal association between 25-dihydroxyvitamin D [25(OH)D] with incident insulin resistance (insulin 
sensitivity score < 8.15) in youth with Type 1 diabetes diagnosed in 2002–2005: SEARCH Nutrition Ancillary 
Study*
Odds ratio (95% CI)† n in model Covariates included in model
Model 1 0.69 (0.56–0.84) 735 Diabetes duration at follow-up and time between visits
Model 2 0.85 (0.63–1.14) 698 Diabetes duration at follow-up, time between visits, age at follow-up visit, season of 
baseline visit, insulin sensitivity score at baseline, race/ethnicity, gender, insulin regimen, 
human leucocyte antigen (HLA) genotype, clinical site
Model 3 0.86 (0.62–1.21) 361 Model 2 covariates, physical activity at baseline and change in physical activity
Model 4‡ — 34 Model 2 covariates, pubertal status at baseline and change in pubertal status
Model 5 0.88 (0.65–1.20) 690 Model 2 covariates, BMI z-score at baseline and BMI change
*
Logistic regression models were used to predict insulin resistance (< 8.15 vs. ≥ 8.15) by 25(OH)D (continuous).
†
Odds ratios and 95% confidence intervals were obtained by comparing a difference of 40 nmol/l in 25(OH)D [25(OH)D = 25 nmol/l (at risk of 
deficiency) vs. 25(OH)D = 65 nmol/l (sufficient)].
‡
Model was not fitted because of the small sample size with change in pubertal status measured.
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